Dr. Rule on Long-Term Follow-Up of Ibrutinib Monotherapy in Relapsed/Refractory MCL

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

Simon Rule, MD, professor of hematology, University of Plymouth, discusses long-term follow-up data from a pooled analysis of ibrutinib (Imbruvica) monotherapy in patients with relapsed/refractory mantle cell lymphoma (MCL).

<<< View more from 2019 ASH Annual Meeting

Related Videos
View All
Related Content